Search details
1.
Molecular and clinical presentation of UBA1-mutated myelodysplastic syndromes.
Blood
; 2024 04 30.
Article
in English
| MEDLINE | ID: mdl-38687605
2.
Demethylation and Up-Regulation of an Oncogene after Hypomethylating Therapy.
N Engl J Med
; 386(21): 1998-2010, 2022 05 26.
Article
in English
| MEDLINE | ID: mdl-35613022
3.
Cardiac effects of deferasirox in transfusion-dependent patients with myelodysplastic syndromes: TELESTO study.
Br J Haematol
; 204(5): 2049-2056, 2024 May.
Article
in English
| MEDLINE | ID: mdl-38343073
4.
DNA methylation profiling of myelodysplastic syndromes and clinical response to azacitidine: A multicentre retrospective study.
Br J Haematol
; 204(5): 1838-1843, 2024 May.
Article
in English
| MEDLINE | ID: mdl-38471524
5.
Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes.
N Engl J Med
; 382(2): 140-151, 2020 01 09.
Article
in English
| MEDLINE | ID: mdl-31914241
6.
Overall survival of myelodysplastic syndrome patients after azacitidine discontinuation and applicability of the North American MDS Consortium scoring system in clinical practice.
Cancer
; 127(12): 2015-2024, 2021 06 15.
Article
in English
| MEDLINE | ID: mdl-33739457
7.
Phospholipase C beta1 (PI-PLCbeta1)/Cyclin D3/protein kinase C (PKC) alpha signaling modulation during iron-induced oxidative stress in myelodysplastic syndromes (MDS).
FASEB J
; 34(11): 15400-15416, 2020 11.
Article
in English
| MEDLINE | ID: mdl-32959428
8.
Clinical and Molecular Insights in Erythropoiesis Regulation of Signal Transduction Pathways in Myelodysplastic Syndromes and ß-Thalassemia.
Int J Mol Sci
; 22(2)2021 Jan 15.
Article
in English
| MEDLINE | ID: mdl-33467674
9.
Neutrophil and platelet increases with luspatercept in lower-risk MDS: secondary endpoints from the MEDALIST trial.
Blood
; 139(4): 624-629, 2022 01 27.
Article
in English
| MEDLINE | ID: mdl-34758066
10.
Nuclear translocation of PKC-α is associated with cell cycle arrest and erythroid differentiation in myelodysplastic syndromes (MDSs).
FASEB J
; 32(2): 681-692, 2018 02.
Article
in English
| MEDLINE | ID: mdl-28970249
11.
Iron-chelating therapy with deferasirox in transfusion-dependent, higher risk myelodysplastic syndromes: a retrospective, multicentre study.
Br J Haematol
; 177(5): 741-750, 2017 06.
Article
in English
| MEDLINE | ID: mdl-28419408
12.
ITACA: A new validated international erythropoietic stimulating agent-response score that further refines the predictive power of previous scoring systems.
Am J Hematol
; 92(10): 1037-1046, 2017 Oct.
Article
in English
| MEDLINE | ID: mdl-28675513
13.
Mutational profile and haematological response to iron chelation in myelodysplastic syndromes (MDS).
Br J Haematol
; 185(5): 954-957, 2019 06.
Article
in English
| MEDLINE | ID: mdl-30407614
14.
Effects of erythropoiesis-stimulating agents on overall survival of International Prognostic Scoring System Low/Intermediate-1 risk, transfusion-independent myelodysplastic syndrome patients: a cohort study.
Haematologica
; 104(1): e4-e8, 2019 01.
Article
in English
| MEDLINE | ID: mdl-30076178
15.
Update of the GIMEMA MDS0306 study: Deferasirox for lower risk transfusion-dependent patients with myelodysplastic syndromes.
Eur J Haematol
; 102(5): 442-443, 2019 May.
Article
in English
| MEDLINE | ID: mdl-30776156
16.
Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial).
Eur J Haematol
; 92(6): 527-36, 2014 Jun.
Article
in English
| MEDLINE | ID: mdl-24580147
17.
[The role of iron metabolism in myelodysplastic syndromes]. / Il ruolo del metabolismo del ferro nelle sindromi mielodisplastiche.
Recenti Prog Med
; 105(3): 123-6, 2014 Mar.
Article
in Italian
| MEDLINE | ID: mdl-24675455
18.
[Molecular biology in myelodysplastic syndromes and acute myeloid leukemias "smoldering"]. / Biologia molecolare nelle sindromi mielodisplastiche e nelle leucemie acute mieloidi "smoldering"
Recenti Prog Med
; 105(3): 118-22, 2014 Mar.
Article
in Italian
| MEDLINE | ID: mdl-24675454
19.
Detection of Cancer Stem Cells in Normal and Dysplastic/Leukemic Human Blood.
Methods Mol Biol
; 2777: 163-176, 2024.
Article
in English
| MEDLINE | ID: mdl-38478343
20.
Activity and safety of eltrombopag in combination with cyclosporin A as firstline treatment of adults with severe aplastic anaemia (SOAR): a phase 2, single-arm study.
Lancet Haematol
; 11(3): e206-e215, 2024 Mar.
Article
in English
| MEDLINE | ID: mdl-38335978